

Full Year 2019 Results

2019 Sales

\$82.1B | Worldwide Increased ▲ **0.6%** | Excluding acquisitions/divestitures on an operational basis | Worldwide Increased ▲ **4.5%***

Diluted Earnings Per Share

\$5.63 | Increased ▲ **0.4%**

Adjusted Diluted Earnings Per Share*

\$8.68 | Increased ▲ **6.1%**



Alex Gorsky
Chairman and
Chief Executive Officer
Johnson & Johnson

“We delivered strong underlying sales and earnings growth in 2019, driven by the strength of our Pharmaceutical business, accelerating performance in our Medical Devices business and improved profitability in our Consumer business. As we enter into 2020 and this next decade, our strategic investments focused on advancing our pipelines and driving innovation across our entire product portfolio, position us well to deliver long-term sustainable growth and value to our shareholders. I am extremely proud of our talented and dedicated colleagues who live Our Credo values each and every day, and are inspired to deliver transformative healthcare solutions that improve the lives of our patients and consumers around the world.”

**\$13.9
Billion**

Worldwide Consumer Sales

Consumer worldwide reported sales increased 0.3% or 3.0% operationally¹. Primary operational contributors:



Neutrogena


Imodium



**\$42.2
Billion**

Worldwide Pharmaceutical Sales


Pharmaceutical worldwide reported sales increased 3.6% or 5.8% operationally¹. Primary operational contributors:



**\$26.0
Billion**

Worldwide Medical Devices Sales

Medical Devices worldwide reported sales decreased (3.8)% or (1.7)% operationally¹. Primary operational contributors:



Electrophysiology

ACUVUE®
Contact Lenses

Wound Closure

Energy

Endcutters

Trauma

Cerenovus

Biosurgery

Hips

Note: values may have been rounded

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson's earnings release issued on January 22, 2020, available at <http://www.investor.jnj.com/sales-earnings.cfm>.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

¹Non-GAAP measure; excludes the impact of translational currency.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on January 22, 2020, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.